ClinicalTrials.gg
Active, not recruitingNCT06745323DeLLphi-309Updated Oct 6, 2026

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

A Phase 2 interventional study of Tarlatamab in Small Cell Lung Cancer (SCLC), sponsored by Amgen. Active, not recruiting at 78 sites in 16 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing AMG 757 in Small Cell Lung Carcinoma — 9 open to participants now, 17 under way, 6 of them phase 3. AMG 757 · Small Cell Lung Carcinoma.

Enrollment
8th of 18
252 · median 221
Started
2025
with 4 others
Phase 2
7 of 18
5 open now
Primary completion
2029-08
later than 11 of 16 live
Registered
7th of 18
by date
Lead sponsor
11 of 18
Amgen

Among the 18 studies testing AMG 757 in Small Cell Lung Carcinoma, this one is the 8th largest by enrollment, is one of 5 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 11 of the 16 other live ones, and was the 7th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 18 studies testing AMG 757 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About AMG 757

AMG 757: first FDA approval 2024 (IMDELLTRA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing AMG 757 in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).

03

Conditions studied

  • Small Cell Lung Cancer (SCLC)

Keywords

  • Tarlatamab
  • AMG 757
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided prior to initiation of any study specific activities/procedures.
  • Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
  • or cytologically confirmed SCLC with demonstrated progression or relapse.
  • Participants who progressed or recurred following 1 platinum-based regimen.
  • as defined per 1.1 within the 21-day screening period.
  • (ECOG) PS of 0 or 1.
  • Minimum of 12 weeks.
  • Adequate organ function as described per protocol.

Exclusion criteria

Exclusion Criteria:

  • Disease Related

    • Previous diagnosis of transformed non-small cell lung cancer (NSCLC) including epidermal growth factor receptor activating mutation positive NSCLC that has transformed to SCLC.
    • Symptomatic central nervous system (CNS) with exceptions defined in the protocol.
  • Other Medical Conditions

    • History of other within the past 2 years, with exceptions defined in the protocol.
    • Evidence of interstitial lung disease or active, non-infectious pneumonitis
    • Diagnosis or evidence of .
    • Active disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring therapy while on study.
    • History of solid organ transplantation.
    • Myocardial infarction and/or symptomatic congestive heart failure ( > class II) within 6 months prior to first dose of study treatment.
    • History of arterial thrombosis (eg, stroke or ) within 6 months prior to first dose of study treatment
    • Presence or history of viral infection based on criteria per protocol.
    • Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7 days prior to the first dose study treatment.
    • Known or active infection requiring parenteral antibiotic treatment.
    • History of severe or life-threatening events from any immune-mediated therapy.
    • Major surgical procedures within 21 days of prior to first dose of study treatment.
  • Prior/Concomitant Therapy

    • Prior anticancer therapy within 30 days of enrollment (14 days for conventional chemotherapy).
    • Prior enrollment on a tarlatamab clinical trial OR prior therapy with any selective inhibitor of the DLL3 pathway.
    • Current anti-cancer therapy such as chemotherapy, immunotherapy, or targeted therapy with exceptions.
    • Receiving systemic therapy or any other immunosuppressive therapy within 7 days prior to first dose as described per protocol.
    • Live and within 14 days prior to the start of study treatment. Inactive vaccines and live viral non-replicating vaccines within 3 days prior to the first dose of study treatment.
  • Prior/Concurrent Clinical Study Experience

    • Currently receiving treatment in another device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
  • Other Exclusions

    • Female participants of unwilling to use protocol specified method of during treatment and for an additional 60 days after the last dose of tarlatamab.
    • Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of tarlatamab.
    • Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of tarlatamab.
    • Female participants of childbearing potential with a positive pregnancy test assessed at screening and/or day 1 by a highly sensitive urine or serum pregnancy test.
    • Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of tarlatamab.
    • Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of tarlatamab.
    • Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of tarlatamab.
    • Participant has known sensitivity or is to any of the products or components to be administered during dosing.
    • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures.
    • History or evidence of any other disorder, condition or disease determined by the investigator or Amgen physician, if consulted, would pose a risk to the subject safety or interfere with the study evaluation procedure or completion.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Treatment Arm A: Dose 1 Tarlatamab

    Participants will receive dose 1 of Tarlatamab by intravenous (IV) infusion during the treatment period.

    Drug: Tarlatamab

  • Experimental
    Treatment Arm B: Dose 2 Tarlatamab

    Participants will receive dose 2 of Tarlatamab by IV infusion during the treatment period.

    Drug: Tarlatamab

  • Experimental
    Treatment Arm C: Dose 3 Tarlatamab

    Participants will receive dose 3 of Tarlatamab by IV infusion during the treatment period.

    Drug: Tarlatamab

Interventions

  • Tarlatamab will be administered by IV infusion.

    Also known as: AMG 757

06

What researchers measure

Primary outcomes

  1. Proportion of participants with confirmed objective response to Tarlatamab

    Time frame: Approximately 52 Months

  2. Proportion of participants with complete response to Tarlatamab

    Time frame: Approximately 52 Months

  3. Proportion of participants with partial response to Tarlatamab

    Time frame: Approximately 52 Months

Secondary outcomes

  1. Average serum concentrations of Tarlatamab

    Time frame: Approximately 52 Weeks

  2. Duration of confirmed response, defined as the time from the first documentation of OR until the first documentation of disease progression or death

    Time frame: Approximately 52 Months

  3. Disease control, defined as objective response or stable disease

    Time frame: Approximately 52 Months

  4. Duration of disease control

    Time frame: Approximately 52 Months

  5. Progression-free survival, defined as the time from randomization to the first documentation of disease progression or death due to any cause

    Time frame: Approximately 52 Months

  6. Objective response, defined as best overall response of CR or PR

    Time frame: Approximately 52 Months

  7. Overall survival, defined as the time from randomization to death due to any cause

    Time frame: Approximately 52 Months

  8. Overall Survival rate at 6 months and 1 year from randomization

    Time frame: Approximately 52 Months

  9. Number of participants with treatment-emergent adverse events

    Time frame: Approximately 52 Months

  10. Number of participants with anti-tarlatamab antibody formation

    Time frame: Approximately 52 Months

07

Study locations

78 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2029, 53 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's planned 53 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion May 2029 → Aug 2029 and completion May 2029 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
Feb 26, 2025
Primary completionEst.
Aug 10, 2029was May 2029
CompletionEst.
Aug 10, 2029was May 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 10, 2029→Aug 10, 2029
Oct 6, 2026
Study completion
May 10, 2029→Aug 10, 2029
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion May 10, 2029→Aug 10, 2029
    Study completion May 10, 2029→Aug 10, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06745323
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Feb 26, 2025
Primary completion
Aug 10, 2029 (estimated)
Completion
Aug 10, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMG 757

Start the discussion